Correlation between the Serum Values of Soluble Intercellular Adhesion Molecule-1 and Total Sialic Acid Levels in Patients with Breast Cancer

Abstract

Background: In this study, we aimed to investigate serum total sialic acid (TSA) and soluble intracellular adhesion molecule-1 (sICAM-1) levels in breast cancer patients to find a correlation with the cancer stage. Methods: The parameters from sera of 61 patients with breast cancer were measured. The concentrations of serum sICAM-1 and TSA were measured in serum samples from 61 patients with breast cancer and 25 healthy control subjects using enzyme-linked immunoassay and thiobarbituric acid method. Results: Mean serum sICAM-1 and TSA levels were significantly higher in the total patient group than in the control group (p < 0.001). Thus, the correlation between TSA and sICAM-1 became more significant in metastatic breast cancer. There were significant positive correlations between TSA and sICAM-1 in stage I+II (r = 0.59, p < 0.05), stage III (r = 0.47, p < 0.05), and stage IV (r = 0.89, p < 0.01), and total patient group (r = 0.56, p < 0.001). Conclusion: SerumsICAM-1 and TSA levels were higher in patients with breast cancer, than that of the control group, and also in the metastatic breast cancer group. Significant correlations between serum sICAM-1 and TSA may reflect the similar function of these molecules as adhesion molecules, and their roles in the carcinogenesis of breast cancer as well as metastasis.

Serum Levels of Glycoproteins are Elevated in Patients with Ovarian Cancer

“…Many recent studies reported higher values of serum glycoproteins in various types of malignant conditions that include malignant melanoma [24,25], breast cancer [18,26], colorectal [27], gynecological [16], oral cancers [28]. Therefore, present study results are in consonance with previously reported findings.…”

“…The level of different types of serum glycoproteins are maintained within a narrow range in health [10], but is elevated in many pathological conditions viz. tuberculosis [11], autoimmune disease [12], cardiovascular disease [13,14], diabetes mellitus [15], cancer of cervix [16], uterus [17] and breasts [18], and arthritis [19]. Thus, it is of great interest to identify and validate serum glycoproteins whose change in levels may provide new insight into cancer progression and may have utility as potential markers for cancer diagnosis.…”

Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression

“…During inflammatory and immune responses, ICAM-1 expressed on endothelial cells (EC) associates with lymphocyte function-associated antigen-1 (LFA-1) and macrophage antigen-1 (Mac-1) presented on leukocytes easing the invasion of damaged tissue by immune cells [13]. Due to its presence on many cancer cell types [12,[14][15][16][17], up-regulation of its soluble form in cancer patients [18,19] and potential role in metastasis [16,20,21], ICAM-1 expression may serve as an important diagnostic tool for assessing tumor prognosis and progression as well as its potential as a target for therapeutic intervention.…”

Modulation of the association between plasma intercellular adhesion molecule-1 and cancer risk by n-3 PUFA intake: a nested case-control study

“…Several prevalent case-control studies have observed higher circulating concentrations of sICAM-1 in cancer cases compared with controls for various cancer sites (1,7,8). Genetic studies have shown that some single nucleotide polymorphisms of the ICAM-1 gene were associated with an increased cancer risk (20)(21)(22)(23), although this point is debated (24).…”

“…Mechanistic studies have shown that ICAM-1 could stimulate angiogenesis and neovascularization (4,5) and promote tumor growth (3) and cell migration (6). In epidemiologic crosssectional studies, concentrations of sICAM-1 were elevated in patients with various cancers (1,7,8). However, prospective studies investigating the association between prediagnostic concentrations of sICAM-1 and cancer risk are lacking.…”